Asymmetry indicates more severe and active disease in Graves’ orbitopathy
results from a prospective cross-sectional multicentre study

Perros, P.; Žarković, M. P.; Panagiotou, G. C.; Azzolini, C.; Ayvaz, G.; Baldeschi, L.; Bartalena, L.; Boschi, A. M.; Nardi, M.; Brix, T. H.; Covelli, D.; Daumerie, C.; Eckstein, A. K.; Fichter, N.; Ćirić, S.; Hagedøs, L.; Kahaly, G. J.; Konuk, O.; Lareida, J. J.; Okosie, O. E.; Leo, M.; Mathiopoulou, L.; Clarke, L.; Menconi, F.; Morris, D. S.; Orgiazzii, J.; Pitz, S.; Salvi, M.; Muller, I.; Knæžević, M.; Wiersinga, W. M.; Currò, N.; Dayan, C. M.; Marcocci, C.; Marinò, M.; Möller, L.; Pearce, S. H.; Torüner, F.; Bernard, M.; Perros, P.; Lareida, J. J.; The European Group on Graves’ Orbitopathy

Published in:
Journal of Endocrinological Investigation

DOI:
10.1007/s40618-020-01258-w

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for pulished version (APA):
Perros, P., Žarković, M. P., Panagiotou, G. C., Azzolini, C., Ayvaz, G., Baldeschi, L., Bartalena, L., Boschi, A. M., Nardi, M., Brix, T. H., Covelli, D., Daumerie, C., Eckstein, A. K., Fichter, N., Ćirić, S., Hagedøs, L., Kahaly, G. J., Konuk, O., Lareida, J. J., ... The European Group on Graves’ Orbitopathy (2020). Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 43(12), 1717-1722. https://doi.org/10.1007/s40618-020-01258-w

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying this open access version.
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study

P. Perros1 · M. P. Žarković2 · G. C. Panagiotou1 · C. Azzolini3 · G. Ayvaz4 · L. Baldeschi5 · L. Bartalena6 · A. M. Boschi5 · M. Nardi7 · T. H. Brix8 · D. Covelli9 · C. Daumerie10 · A. K. Eckstein11 · N. Fichter12 · S. Ćirić13 · L. Hegedüs8 · G. J. Kahaly14 · O. Konuk15 · J. J. Lareida12 · O. E. Okosie16 · M. Leo17 · L. Mathiopoulou1 · L. Clarke18 · F. Menconi17 · D. S. Morris19 · J. Orgiazz120 · S. Pitz21 · M. Salvi9 · I. Muller9 · M. Knežević22 · W. M. Wiersinga23 · N. Currò24 · C. M. Dayan16 · C. Marcocci17 · M. Marinò17 · L. Möller12 · S. H. Pearce1 · F. Torüner25 · M. Bernard26 · The European Group on Graves’ Orbitopathy

Received: 14 March 2020 / Accepted: 13 April 2020 © The Author(s) 2020

Abstract

Purpose Patients with Graves’ orbitopathy can present with asymmetric disease. The aim of this study was to identify clinical characteristics that distinguish asymmetric from unilateral and symmetric Graves’ orbitopathy.

Methods This was a multi-centre study of new referrals to 13 European Group on Graves’ Orbitopathy (EUGOGO) tertiary centres. New patients presenting over a 4 month period with a diagnosis of Graves’ orbitopathy were included. Patient demographics were collected and a clinical examination was performed based on a previously published protocol. Patients were categorized as having asymmetric, symmetric, and unilateral Graves’ orbitopathy. The distribution of clinical characteristics among the three groups was documented.

Results The asymmetric group (n = 83), was older than the symmetric (n = 157) group [mean age 50.9 years (SD 13.9) vs 45.8 (SD 13.5), p = 0.019], had a lower female to male ratio than the symmetric and unilateral (n = 29) groups (1.6 vs 5.0 vs 8.7, p < 0.001), had more active disease than the symmetric and unilateral groups [mean clinical Activity Score 3.0 (SD 1.6) vs 1.7 (SD 1.7), p < 0.001 vs 1.3 (SD 1.4), p < 0.001] and significantly more severe disease than the symmetric and unilateral groups, as measured by the Total Eye Score [mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), p < 0.001, vs 2.7 (SD 2.1), p < 0.001].

Conclusion Older age, lower female to male ratio, more severe, and more active disease cluster around asymmetric Graves’ orbitopathy. Asymmetry appears to be a marker of more severe and more active disease than other presentations. This simple clinical parameter present at first presentation to tertiary centres may be valuable to clinicians who manage such patients.

Keywords Graves’ · Orbitopathy · Thyroid · Asymmetric · Unilateral

Introduction

Graves’ orbitopathy (GO) is an orbital disorder closely associated with autoimmune thyroid disease [1]. GO is responsible for considerable psychosocial morbidity, personal and societal cost [2, 3], can rarely cause blindness [4], and is associated with increased mortality including that from suicide [5, 6]. Most patients present with bilateral disease though asymmetric or unilateral disease is also observed in a minority of cases. The prevalence of unilateral disease is 4.5–14% [7–11], while asymmetric disease is reported to occur in 9–34% of patients with GO [9–12]. Although the underlying pathogenesis of all forms of GO is likely to be the same and based on autoimmunity, asymmetric and unilateral GO may differ in the relative contributions of mechanical and inflammatory influences as well as local vascular or anatomical factors. The objective of this study was to analyze data from a prospective cross-sectional multi-centre study [13] and identify

All authors are members of the European Group on Graves’ Orbitopathy.

* P. Perros petros.perros@ncl.ac.uk

Extended author information available on the last page of the article

Published online: 30 May 2020 © Springer
clinical characteristics that distinguish asymmetric, unilateral and bilateral symmetric GO.

**Methods**

**Patients**

All new referrals of patients with a diagnosis of GO to EUGOGO centres were recruited prospectively during a 4-month period between 1st September 2012 and 31st December 2012. Data were collected during their first consultation as described in Perros et al. [13].

**Assessments**

Ophthalmic signs were assessed according to established EUGOGO protocols [13]. All assessors had received specialist training in the clinical evaluation of patients with GO and had attended at least one EUGOGO teaching course. Detailed description of assessments can be found in Perros et al. [13]. Unilateral disease was defined as one or more clinical features of GO in one eye without any evidence of GO in the contralateral eye. Asymmetric GO was defined as disease present in both eyes with one or more of the following features: difference between the two eyes in exophthalmometer readings by two or more mm; difference in palpebral aperture by two or more millimeter, difference in eyelid swelling by one or more grades; difference in eyelid erythema by one or more grades; difference in conjunctival redness by one or more grades; presence of dysthyroid optic neuropathy in one eye only. Duration of GO was ascertained based on the patient’s history. This study was observational to aid audit and service development by EUGOGO centres, and ethical committee approval was deemed not to be necessary [13]. Confidentiality was preserved by pseudoanonymizing the data (pseudonymization substitutes the identity of the data subject in such a way that additional information is required to reidentify the data subject). The described research adhered to the tenets of the Declaration of Helsinki.

**Statistical analyses**

To compare clinical characteristics, group linear model ANOVA was used [14]. Pearson Chi-square tests or Fisher’s exact test and trend test for ordinal variables were used where appropriate. The software “R” was used for statistical analysis.

**Results**

There were 269 patients with a diagnosis of GO of whom 157 had symmetric (58.4%), 83 asymmetric (30.9%) and 29 (10.7%) unilateral disease. Although there was an overall slight excess of higher right sided exophthalmometer readings, the differences in distribution of exophthalmos measurements between right and left for the entire group, within and between groups, were not statistically significant. The baseline characteristics of patients are shown in Table 1. Comparisons between groups showed that the asymmetric group had an older age than the symmetric group [mean age 50.9 years (SD 13.9) vs 45.8 (SD 13.5), \( p = 0.019 \)], lower female to male ratio than the other two groups (1.6 vs 5.0 vs 8.7, \( p < 0.001 \)), had more active disease than the symmetric and unilateral groups [mean Clinical Activity Score 3.0 (SD

| Table 1 | Clinical characteristics of patients |
|---------|-------------------------------------|
|         | Symmetric | Asymmetric | Unilateral |
| % (No.) | 58.4 (157) | 30.9 (83)  | 10.8 (29)  |
| Age [years, mean (SD)] | 45.8 (13.5) | 50.9 (13.9) | 48.6 (15.2) |
| Female [% (No.)] | 83.4 (130) | 50.9 (13.9) | 48.6 (15.2) |
| Nation [% (No.)] | 83.4 (130) | 50.9 (13.9) | 48.6 (15.2) |
| Belgium | 3.8 (6) | 7.2 (6) | 3.4 (1) |
| Denmark | 2.5 (4) | 0 (0) | 6.9 (2) |
| France | 10.8 (17) | 16.9 (14) | 20.7 (6) |
| Germany | 24.2 (38) | 27.7 (23) | 27.6 (8) |
| Italy | 30.6 (48) | 31.3 (26) | 13.8 (4) |
| Serbia | 6.4 (10) | 8.4 (7) | 0 (0) |
| Switzerland | 7 (11) | 1.2 (1) | 6.9 (2) |
| Turkey | 5.1 (8) | 3.6 (3) | 13.8 (4) |
| UK | 9.6 (15) | 3.6 (3) | 6.9 (2) |
| Previous thyroid treatment [% (No.)] | 17.2 (27) | 15.7 (13) | 24.1 (7) |
| Radioiodine | 22.3 (35) | 22.9 (19) | 17.2 (5) |
| Thyroidectomy | 43.9 (69) | 43.4 (36) | 41.4 (12) |
| Anti-thyroid drugs | 16.6 (26) | 18.1 (15) | 17.2 (5) |
| No treatment | 1.7 (1.7) | 3.0 (1.6) | 1.3 (1.4) |
| CAS [mean (SD)] | 5.3 (4.4) | 8.8 (6.6) | 2.7 (2.2) |
| TES [mean (SD)] | 0.5 (5) | 2.5 (1.6) | 2.2 (2.2) |
| Difference in exophthalmos between right and left eye [mm, mean (SD)] | 1.1 (1.4) | 1.7 (1.6) | 2.1 (1.6) |
| Difference in PA between right and left eye [mm, mean (SD)] | 62 (39.5) | 29 (39.8) | 13 (44.8) |
| Current smoker (No.) | 27.8 (46.1) | 43.2 (98.7) | 22.7 (38.8) |

CAS clinical activity score, TES total eye score, PA palpebral aperture, GO Graves’ orbitopathy

\( a \)Mean (standard deviation); \( b \)worse TES of the two eyes.
and significantly more severe disease than the symmetric and unilateral groups, as measured by the Total Eye Score [mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), \( p < 0.001 \), vs 2.7 (SD 2.1), \( p < 0.001 \)]. The unilateral group had less severe disease than either of the other two groups (\( p < 0.001 \)) (Table 2). There were no significant differences in all other clinical characteristics (country of origin, type of underlying thyroid disease, type of treatment for thyroid disease, time since diagnosis of thyroid disease, duration of GO, coexistent diabetes, family history of thyroid disease, family history of autoimmune disease, smoking). Thus, the asymmetric group emerged as the most distinct compared with the others, with an older mean age, lowest female to male ratio, more active and more severe GO. Pooling the asymmetric and unilateral groups together and comparing them with the symmetric group did not alter the above findings.

**Discussion**

Facial asymmetry is important as it can be a cause of distress to patients [15], including a negative impact on the quality of life in patients with asymmetric GO [16]. Asymmetry is also an intriguing observation in diseases that are thought to be systemic, and further study may provide insights into factors that modulate disease expression. Asymmetrical or unilateral GO may precede bilateral disease in some patients [11, 17], a fact that is of importance in timing of interventions such as rehabilitative surgery. Asymmetry in the anatomy of the bony orbit, optic canal, ophthalmic vessels, length of the globe, and exophthalmometer readings of normal subjects is common [18–20], but whether structural variations in the orbits are more pronounced in patients with asymmetric/unilateral GO is unknown. The prevalence of asymmetric disease in our cohort was 30.9% and that of unilateral disease 10.7%, which is comparable to reports in published literature of asymmetric in 9–34% [9, 10, 12, 16, 17, 22] and unilateral disease in 4.5–14.0% of patients with GO [7–11]. The variations in the above figures between studies are probably due to differences in definitions of asymmetry and unilaterality used, and inter-/intra-observer variation. In addition, differences in the phase of the natural history of GO at the time of assessment may also have contributed, as after the passage of time some patients with unilateral disease develop bilateral features [11, 17]. An association between asymmetric disease and older age [22, 23], more active disease [22], and lower female to male ratio [24], has been previously reported, and our study has confirmed these associations. The clustering of all the above features as well as increased severity around asymmetric GO is a finding that has not been described before. The reason why asymmetry should be associated with older age and a lower female to male ratio is unclear, though an association between older age and male gender with more severe disease has been previously observed [23–25] and may be partly explained by differences in exposure to smoking. The data from this study however, suggest that smoking is an unlikely explanation for this cohort as the rates of smoking were very similar between the asymmetric and symmetric groups and highest in the unilateral group, though the differences were not statistically significant (Table 1). This study also showed that patients with unilateral disease have significantly milder GO than symmetric or asymmetric variants. Possible explanations for this observation include the fact that patients with unilateral mild GO are more likely to be referred to tertiary centres than bilateral or asymmetric GO of similar severity, for exclusion of other diagnoses, in accordance with published guidelines [26], as well as the association of unilateral disease with euthyroidism and low TSH receptor antibodies [27]. The explanation for why asymmetric/unilateral disease occurs, may partly lie in underlying asymmetry of the bony orbit, which is a normal finding in all people [19] as discussed above, however additional contributors are likely to play a role. A previous study tested the hypothesis that sleeping position may be responsible, but no such association was found [12]. It is possible that differences in vascularity between orbits may be at play, although this has not been studied specifically in asymmetric disease. However, differences in arterial and venous flow in orbital vessels in patients with and without GO have been described, as well as in patients with and without dysthyroid optic neuropathy [28]. Other local factors relating to anatomy and properties of soft tissues (e.g. of the elasticity of the orbital septae), asymmetrical distribution of resident inflammatory cells in the orbit and molecular differences in potential for adipogenesis and production of proinflammatory cytokines by orbital

### Table 2 Statistically significant differences between the three groups

|                          | Symmetric | Asymmetric | Unilateral |
|--------------------------|-----------|------------|------------|
| No. (%)                  | 157 (58.4)| 83 (30.9)  | 29 (10.8)  |
| Age [years, mean (SD)]\(^a\) | 45.8 (13.5)| 50.9 (13.9)| 48.6 (15.2)|
| Female (No. %)\(^b\)     | 130 (83.4)| 74 (61.4)  | 26 (89.7)  |
| CAS [mean (SD)]\(^c\)     | 1.7 (1.7) | 3.0 (1.6)  | 1.3 (1.4)  |
| TES [mean (SD)]\(^d,e\)   | 5.3 (4.4) | 8.8 (6.6)  | 2.7 (2.2)  |

CAS clinical activity score, TES total eye score

\(^a\) asymmetric vs symmetric \( p = 0.019 \);

\(^b\) asymmetric vs symmetric and asymmetric vs unilateral, \( p < 0.001 \);

\(^c\) asymmetric vs symmetric and asymmetric vs unilateral, \( p < 0.001 \);

\(^d\) asymmetric vs symmetric and asymmetric vs unilateral, \( p < 0.001 \);

\(^e\) unilateral vs symmetric, \( p < 0.001 \)

---

[51x76]p < 0.001 vs 1.3 (SD 1.4), \( p < 0.001 \).
tissues, and unilateral triggers such as infection, may also contribute. The natural history of asymmetric and unilateral disease is not well studied, but the available evidence suggests that in a significant proportion of patients with unilateral disease (14–36%), bilaterality eventually ensues in due course [11,17], so the natural course of the disease in one orbit may lag behind the other. The strengths of our study were the large number of patients included, its multi-centre and multi-national design, clinical assessments based on well-defined protocols, and prospective recruitment over a 4 month period simultaneously by all centres. Weaknesses included absence of detailed motility data (other than Gorman score), potential errors due to multiple observer variation, lack of imaging studies and absence of longitudinal follow-up data, which is crucial in understanding how these subtypes of GO inter-relate, progress from one to another and, most importantly, how do they respond to therapy. The management of GO can be difficult and it is recommended that all but the mildest of cases are referred to tertiary centres [26]. It is not known whether early intervention diminishes the risk or incidence of asymmetric disease, or whether the ultimate prognosis is worse than other phenotypes in terms of disease severity, and associated psycho-social burden, although a negative association with quality of life has been reported [16]. Nonetheless, medical treatments are most effective during the active phase of the disease and recognizing and focusing resources during this window is important. Our data suggest that asymmetry may be a marker of greater disease activity and severity, which can be a useful indicator for prioritizing cases when referrals are received by tertiary centres. In conclusion, this study has shown that asymmetric GO is associated with older age, a lower female to male ratio, more active and more severe disease than symmetric or unilateral GO. Clinicians who manage patients with GO should be aware that patients with asymmetric GO have more active and more severe disease.

Acknowledgements The authors wish to thank Jane Dickinson, Carol Lane, John Lazarus, Dagmar Fuerer, and Christopher Neoh for supporting this work.

Funding None.

Data availability From corresponding author.

Code availability Not applicable.

Compliance with ethical standards

Conflict of interest The author(s) declare that they have no conflict of interest.

Ethical approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Smith TJ, Hegedüs L (2016) Graves’ disease. N Engl J Med 375:1552–1565
2. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 98:145–152
3. Nexo MA, Watt T, Pedersen J, Bonnema SJ, Hegedüs L, Rasmussen AK et al (2014) Increased risk of long-term sickness absence, lower rate of return to work, and higher risk of unemployment and disability pensioning for thyroid patients: a Danish register-based cohort study. J Clin Endocrinol Metab 99:3184–3192
4. Mc Keag D, Lane C, Lazarus JH, Baldeschl, Boboridis K, Dickinson AJ et al (2007) European Group on Graves’ Orbitopathy (EUGOGO). Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91:455–458
5. Schwensen CF, Brandt F, Hegedüs L, Brix TH (2017) Mortality in Graves’ orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study. Eur J Endocrinol 176:669–676
6. Ferkov-Schwensen C, Brix TH, Hegedüs L (2017) Death by suicide in Graves’ disease and Graves’ orbitopathy: a Nationwide Danish Register Study. Thyroid 27:1475–1480
7. Wiersingsa WM, Smit T, van der Gaag R, Mourits M, Koornneef L (1989) Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res 21:73–92
8. Bartley GB (1994) The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92:477–588
9. Prummel MF, Bakker A, Wiersinga WM, Baldeschli, Mourits MP, Kendall-Taylor P et al (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 148:491–495
10. Soroudi AE, Goldberg RA, McCann JD (2004) Prevalence of asymmetric exophthalmos in Graves orbitopathy. Ophthalm Plast Reconstr Surg 20:224–225
11. Daumerie Ch, Duprez T, Bosch A (2008) Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy. Eur J Intern Med 19:531–536
12. Wiersinga WM, Bleumink M, Saed P, Baldeschli, Prummel MF (2008) Is sleeping position related to asymmetry in bilateral Graves’ ophthalmopathy? Thyroid 18:541–544
13. Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L et al (2015) PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99:1531–1535

14. Pinheiro J, Bates D, DebRoy S, Sarkar D, Heisterkamp S, Bert Van Willigen (2008) Nonlinear mixed effects models. https://CRAN.R-project.org/package=nlme. Accessed 14 Mar 2020.

15. Shackelford TK, Larsen RJ (1997) Facial asymmetry as an indicator of psychological, emotional, and physiological distress. J Pers Soc Psychol 72:456–466

16. Villagelin D, Romaldini J, Andrade J, Santos R, Milkos A, Dos Santos Teixeira PF et al (2019) Evaluation of quality of life in the Brazilian Graves’ disease population: focus on mild and moderate Graves’ orbitopathy patients. Front Endocrinol (Lausanne) 10:192

17. Strianese D, Piscopo R, Elefante A, Napoli M, Comune C, Baroni P et al (2013) Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study. BMC Ophthalmol 13:21

18. Kashkouli MB, Nojomi M, Parvash MM, Sanjari MS, Modarres M et al (2008) Normal values of Hertel exophthalmometry in children, teenagers, and adults from Tehran. Iran Optom Vis Sci 85:1012–1017

19. Seiji F, Moreira RS, De Angelis MA, Smith Chairman RL (2009) Orbital asymmetry in development: an anatomical study. Orbit 28:342–346

20. Tsutsumi S, Nakamura M, Tabuchi T, Yasumoto Y (2015) The superior ophthalmic vein: delineation with high-resolution magnetic resonance imaging. Surg Radiol Anat 37:75–80

21. Zhang X, Lee Y, Olson D, Fleischman D (2019) Evaluation of optic canal anatomy and symmetry using CT. BMJ Open Ophthalmol 4:e000302

22. Kavoussi SC, Giacometti JN, Servat JJ, Levin F (2014) The relationship between sex and symmetry in thyroid eye disease. Clin Ophthalmol 8:1295–1300

23. Kendler DL, Lippa J, Rootman J (1993) The initial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol 111:197–201

24. Li Q, Ye H, Ding Y, Chen G, Chen G, Liu Z, Xu J et al (2017) Clinical characteristics of moderate-to-severe thyroid associated orbitopathy in 354 Chinese cases. PLoS ONE 12:e0176064

25. Perros P, Cromptie AL, Matthews JN, Kendall-Taylor P (1993) Age and gender influence the severity of thyroid-associated orbitopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38:367–372

26. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marconi C et al (2008) Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18:233–246

27. Eckstein AK, Lösch C, Glowacka D, Schott M, Mann K, Esser J et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 93:1052–1056

28. Pérez-López M, Sales-Sanz M, Rebolleda G, Casas-Llera P, González-Gordialca C, Jarrín E et al (2011) Retrobulbar ocular blood flow changes after orbital decompression in Graves’ ophthalmopathy measured by color Doppler imaging. Invest Ophthalmol Vis Sci 52:5612–5617

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

P. Perros1,2 · M. P. Žarković2 · G. C. Panagiotou1 · C. Azzolini3 · G. Ayvaz4 · L. Baldeschi5 · L. Bartalena6 · A. M. Boschi5 · M. Nardi7 · T. H. Brix8 · D. Covelli9 · C. Daumerie10 · A. K. Eckstein11 · N. Fichter12 · S. Ćirić13 · L. Hegedüs8 · G. J. Kahaly14 · O. Konuk15 · J. J. Lareida12 · O. E. Okosieme16 · M. Leo17 · L. Mathiopoulou1 · L. Clarke18 · F. Menconi17 · D. S. Morris19 · J. Orgiazzi20 · S. Pitz21 · M. Salvi9 · I. Muller9 · M. Knežević22 · W. M. Wiersinga23 · N. Currò24 · C. M. Dayan16 · C. Marcocci17 · M. Marinò17 · L. Möller12 · S. H. Pearce1 · F. Töröner25 · M. Bernard26 · The European Group on Graves’ Orbitopathy

1 Department of Endocrinology, Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, Tyne, UK

2 Faculty of Medicine, University of Belgrade, Dr Subotića 8, Belgrade, Serbia

3 Department of Medicine and Surgery, Section of Ophthalmology, School of Medicine, University of Sibiu, Via Giucchiardi 9, 21100 Varese, Italy

4 Department of Endocrinology, Yüksek İhtisas University Ankara Koru Hastanesi, 1450, Sk. No:13, Kızılirmak, 06510 Çankaya, Ankara, Turkey

5 Department of Ophthalmology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium

6 Endocrine Unit, University of Sibiu, Ospedale di Circolo, Viale Borri, 57 21100 Varese, Italy

7 Dipartimento di Patologia Chirurgica Medica, Molecolare e Dell’Area Critica, Università di Pisa, Pisa, Italy

8 Department of Endocrinology and Metabolism, Odense University Hospital, 5000 Odense, Denmark

9 Graves’ Orbitopathy Center, Endocrinology, Fondazione IRCCS Cà Granda, University of Milan, via Sforza, 35 - I-20122, Milan, Italy

10 Department of Endocrinology, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium

11 Department of Ophthalmology, University of Duisburg-Essen, 45122 Essen, Germany

12 Interdisciplinary Centre for Graves’ Orbitopathy, 4600 Olten, Switzerland

13 Clinic of Endocrinology, Clinical Centre of Serbia, Belgrade, Serbia
